// App-Quantinova.ai

: The efficacy and safety of colistimethate sodium delivered via the I-neb in bronchiectasis: the PROMIS-I randomized controlled trial

Researchers

Presenter

  • Charles S Haworth

Principal Investigators

  • Michal Shteinberg

  • Kevin L Winthrop

  • Francesco Blasi

  • Katerina Dimakou

  • Lucy Morgan

  • Felix C Ringshausen

  • Oriol S Vidal

  • Rachel Thompson

  • Kelly Sharp

  • Ischa Vissers

  • Dearbhla Hull

  • James D Chalmers

Medical Centers

  • Rambam Medical Center, Haifa, Israel

  • Concord Hospital, Sydney NSW, Australia

  • Syneos Health, Farnborough, United Kingdom

  • Papworth Hospital, Cambridge, United Kingdom

  • Oregon Health & Science University, Portland, United States of America

  • University of Dundee, Dundee, United Kingdom

  • Sotiria General Hospital, Athens, Greece

  • Zambon SpA, Chichester (West Sussex), United Kingdom

  • Zambon SpA, Bresso, Italy

  • University of Queensland School of Medicine, Brisbane, Queensland, Australia

  • Universita' Degli Studi di Milano, Milano, Italy.

  • Medizinische Hochschule Hannover, Hannover, Germany

  • Hospital Santa Creu i Sant Pau, Barcelona, Spain

Locations

  • United States

  • United Kingdom

  • Israel

  • Germany

  • Italy

  • Australia

  • Greece

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

  • Autoimmune (AI)

Disease

  • Cystic Fibrosis

  • Asthma

Biomarkers

  • N/A

Drug/Treatment

  • Colistimethate sodium

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved